As of January 22, 2025, 89bio (ETNB) has a market cap of $0.79 billion USD. According to our data, 89bio is ranked No.5532 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.79 B |
-13.68%
|
Dec 31, 2024 | $0.92 B |
-29.99%
|
Dec 29, 2023 | $1.31 B |
-12.25%
|
Dec 30, 2022 | $1.50 B |
-2.60%
|
Dec 31, 2021 | $1.54 B |
-46.37%
|
Dec 31, 2020 | $2.87 B |
-7.30%
|
Dec 31, 2019 | $3.09 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Madrigal Pharmaceuticals
MDGL
|
$7.08 B |
-0.000 M
|
USA
|
Viking Therapeutics
VKTX
|
$3.79 B |
-0.000 M
|
USA
|
Akero Therapeutics
AKRO
|
$1.75 B |
0.000 M
|
USA
|
Galmed Pharmaceuticals
GLMD
|
$4.72 M |
0.000 M
|
Israel
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Genfit
GNFT
|
$0.18 B |
-0.000 M
|
France
|
Arrowhead Pharmaceuticals
ARWR
|
$2.45 B |
-0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
FibroGen
FGEN
|
$50.79 M |
0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
Market Cap | = | ETNB Stock Price | * | ETNB Shares Outstanding |
= | $6.75 | * | 0.12 B | |
= | $0.79 B |